/BUX.CN
BUX.CN Stock - BioMark Diagnostics Inc.
Healthcare|Medical - Diagnostics & ResearchCNQ
$0.46+4.55%
+$0.02 (+4.55%) • Dec 22
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BUX.CN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.46 – $0.46
TARGET (TP)$0.53
STOP LOSS$0.42
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.21
52W High$0.50
52W Low$0.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $154,216 | $163,220 | $153,492 | $43,933 | N/A |
| Gross Profit | $154,216 | $163,220 | $-232,704 | $43,933 | $-13,686 |
| Gross Margin | 100.0% | 100.0% | -151.6% | 100.0% | N/A |
| Operating Income | $-1,908,137 | $-1,316,716 | $-1,840,289 | $-1,283,942 | $-1,093,590 |
| Net Income | $-1,927,280 | $-1,427,385 | $-1,842,229 | $-1,453,903 | $-1,094,190 |
| Net Margin | -1249.7% | -874.5% | -1200.2% | -3309.4% | N/A |
| EPS | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.01 |
Company Overview
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BUX.CNBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2023
EPS Surprise History
Q1 21
No data
Q2 21
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Dec 31, 2023 | — | $-0.00 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.00 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.01 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.00 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.00 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BUX.CN
What is BUX.CN's current stock price?
BioMark Diagnostics Inc. (BUX.CN) is currently trading at $0.46 per share. The stock has moved +4.55% today.
What is the analyst price target for BUX.CN?
No analyst price targets are currently available for this stock.
What sector is BioMark Diagnostics Inc. in?
BioMark Diagnostics Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the CNQ exchange.
What is BUX.CN's market cap?
BioMark Diagnostics Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does BUX.CN pay dividends?
No, BioMark Diagnostics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADK.V
DIAGNOS Inc.
$0.35
Mkt Cap: $0.0B
AVCN.TO
Avicanna Inc.
$0.23
Mkt Cap: $0.0B
CWEB.TO
Charlotte's Web Holdings, Inc.
$0.38
Mkt Cap: $0.1B
GLAB.CN
Gemina Laboratories Ltd.
$0.08
Mkt Cap: $0.0B
IZO.CN
Izotropic Corporation
$0.27
Mkt Cap: $0.0B
LABS.TO
MediPharm Labs Corp.
$0.07
Mkt Cap: $0.0B
MBX.TO
Microbix Biosystems Inc.
$0.23
Mkt Cap: $0.0B
PINK.V
Perimeter Medical Imaging AI, Inc.
$0.42
Mkt Cap: $0.0B
ROMJ.V
Rubicon Organics Inc.
$0.47
Mkt Cap: $0.0B
VM.V
Voyageur Pharmaceuticals Ltd.
$0.18
Mkt Cap: $0.0B
Explore stocks similar to BUX.CN for comparison